Advocacy Archives – Treatment Action Group

At This Week’s UN General Assembly High-Level Meeting on Tuberculosis, the 1/4/6×24 Campaign Calls on Political Leaders to Take Urgent Action for Equitable Access to Shorter, Safer TB Regimens

September 19, 2023
Dorrit Walsh

Ahead of the United Nations General Assembly High-Level Meeting on the Fight Against Tuberculosis, the 1/4/6x24 Campaign is sounding the alarm that the political declaration commits neither the funding nor the actions needed to expand access to the best-available TB regimens and diagnostics.

TAG to Honor Leaders of Latino HIV Community, Pediatric Drug-Resistant TB, and Transgender Health at RIAA 2023

September 12, 2023
Dorrit Walsh

Our annual Research in Action Awards (RIAA) event is TAG’s biggest night of the year. On October 19, we’ll be deeply honored to gather with our most cherished supporters and community members to recognize just a few of the many visionaries whose work has brought us closer to ending HIV, TB, and HCV.

HCV Elimination Among People Living with and at Risk of HIV: Challenges and Opportunities

September 5, 2023
Dorrit Walsh

Following the White House’s recent proposal for a National Hepatitis C Elimination Plan as part of its Fiscal Year 2024 budget request to Congress, and the fact that key populations for HIV are also at high risk of HCV, Treatment Action Group is organizing a webinar that will highlight best practices and challenges for HCV elimination with a specific focus on high-burden populations.

Letter to Dr. Jeanne Marazzo, New Director NIAID

August 10, 2023
Dorrit Walsh

We're excited to welcome Dr. Jeanne Marazzo as the first woman and openly LGBTQ+ Director of the National Institute of Allergy and Infectious Diseases (NIAID).

TAG Welcomes Addition of Ravidasvir to WHO Essential Medicines List for Treatment of Hepatitis C Virus

August 2, 2023
Dorrit Walsh

Treatment Action Group welcomes the inclusion of Ravidasvir on the World Health Organization (WHO) Essential Medicines List (EML) as a direct-acting antiviral (DAA) for the treatment of chronic hepatitis C virus (HCV) infection in adults.

Open letter: Requesting Clarification on the Recent Deal on Generic Bedaquiline Supply

August 1, 2023
Dorrit Walsh

TAG, Partners In Health, and MSF Access Campaign sent an open letter to Johnson & Johnson requesting detailed responses to questions and concerns regarding the deal with the Global Drug Facility to supply generic bedaquiline to low- and middle-income countries that excludes South Africa, 10 EECA countries, and China.

Employee Engagement Programs & Affinity Groups: Partner with TAG to Drive Social Impact

July 21, 2023
Dorrit Walsh

At Treatment Action Group (TAG), we recognize the immense potential of collective action in bringing about positive change. That's why we invite companies and organizations to join us in the fight against HIV, hepatitis C (HCV), and tuberculosis (TB) through…

Celebrate and Expand Your Support: Leverage the Power of Your Networks and Social Media

July 21, 2023
Dorrit Walsh

At Treatment Action Group (TAG), we believe in the power of social media to amplify support and spread awareness. By utilizing social media platforms and online communities, you can celebrate your special occasions while expanding your impact and raising awareness…

Join TAG’s Board: Shape the Future of Health Advocacy

July 21, 2023
Dorrit Walsh

Treatment Action Group (TAG) is seeking passionate individuals committed to ending the epidemics of HIV, hepatitis C (HCV), and tuberculosis (TB) to join our oard of directors. As a member of TAG's Board, you will play a pivotal role in…

Donor Advised Funds: Amplify Your Impact with Treatment Action Group

July 21, 2023
Dorrit Walsh

Supporting Treatment Action Group (TAG) through Donor Advised Funds (DAFs) empowers you to maximize the impact of your philanthropy. A Donor Advised Fund is a flexible giving vehicle that allows you to make a charitable contribution, receive an immediate tax…